| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Active surveillance beats surgery in low-risk prostate cancer
|
Brower, Vicki
|
|
2012
|
13 |
11 |
p. e468-
1 p.
|
artikel
|
| 2 |
Aggressive breast cancer genetically similar to ovarian cancer
|
Mayor, Susan
|
|
2012
|
13 |
11 |
p. e466-
1 p.
|
artikel
|
| 3 |
A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study
|
Ross, Robert W
|
|
2012
|
13 |
11 |
p. 1105-1113
9 p.
|
artikel
|
| 4 |
Big pharma looks to ancient China for new cures
|
Alcorn, Ted
|
|
2012
|
13 |
11 |
p. 1080-
1 p.
|
artikel
|
| 5 |
BRAF and MEK inhibitors in BRAF-mutant melanoma
|
Sharma, Sharan Prakash
|
|
2012
|
13 |
11 |
p. e468-
1 p.
|
artikel
|
| 6 |
Can Big Pharma join forces to expedite drug development?
|
Nierengarten, Mary Beth
|
|
2012
|
13 |
11 |
p. e467-
1 p.
|
artikel
|
| 7 |
Cancer charities force government to rethink welfare reforms
|
Senior, Kathryn
|
|
2012
|
13 |
11 |
p. e465-
1 p.
|
artikel
|
| 8 |
Carcinogenicity assessments: WHO decides?
|
The Lancet Oncology,
|
|
2012
|
13 |
11 |
p. 1063-
1 p.
|
artikel
|
| 9 |
Conditional survival of patients with metastatic renal-cell carcinoma
|
Sun, Maxine
|
|
2012
|
13 |
11 |
p. e462-
1 p.
|
artikel
|
| 10 |
Correction to Lancet Oncol 2012; 13: 1028
|
|
|
2012
|
13 |
11 |
p. e464-
1 p.
|
artikel
|
| 11 |
Correction to Lancet Oncol 2012; 13: 983, 986
|
|
|
2012
|
13 |
11 |
p. e464-
1 p.
|
artikel
|
| 12 |
Correction to Lancet Oncol 2012; 13: e468
|
|
|
2012
|
13 |
11 |
p. e464-
1 p.
|
artikel
|
| 13 |
Cubop City Blues
|
Whinder, Frances
|
|
2012
|
13 |
11 |
p. 1085-
1 p.
|
artikel
|
| 14 |
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
|
Long, Georgina V
|
|
2012
|
13 |
11 |
p. 1087-1095
9 p.
|
artikel
|
| 15 |
Dallas reprised
|
Jouret, Jill
|
|
2012
|
13 |
11 |
p. 1084-
1 p.
|
artikel
|
| 16 |
Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy?
|
Ahmed, Hashim Uddin
|
|
2012
|
13 |
11 |
p. e509-e517
nvt p.
|
artikel
|
| 17 |
Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study
|
Ray-Coquard, Isabelle
|
|
2012
|
13 |
11 |
p. 1133-1140
8 p.
|
artikel
|
| 18 |
2012 ESMO congress
|
Ceschia, Audrey
|
|
2012
|
13 |
11 |
p. 1081-
1 p.
|
artikel
|
| 19 |
Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial
|
FOxTROT Collaborative Group,
|
|
2012
|
13 |
11 |
p. 1152-1160
9 p.
|
artikel
|
| 20 |
Fibulin-3 as a biomarker for mesothelioma
|
Burki, Talha Khan
|
|
2012
|
13 |
11 |
p. e469-
1 p.
|
artikel
|
| 21 |
First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial
|
Lee, Siow Ming
|
|
2012
|
13 |
11 |
p. 1161-1170
10 p.
|
artikel
|
| 22 |
Genetic link to male breast cancer
|
Burki, Talha Khan
|
|
2012
|
13 |
11 |
p. e465-
1 p.
|
artikel
|
| 23 |
HIPEC: standard of care or an experimental approach?
|
Evrard, Serge
|
|
2012
|
13 |
11 |
p. e462-e463
nvt p.
|
artikel
|
| 24 |
Improving outcomes for elderly patients with AML
|
Russell, Nigel H
|
|
2012
|
13 |
11 |
p. 1065-1066
2 p.
|
artikel
|
| 25 |
Lighting up the big screen
|
Bennet, Neil
|
|
2012
|
13 |
11 |
p. 1083-
1 p.
|
artikel
|
| 26 |
Management of colon cancer: resource-stratified guidelines from the Asian Oncology Summit 2012
|
Ku, Geoffrey
|
|
2012
|
13 |
11 |
p. e470-e481
nvt p.
|
artikel
|
| 27 |
Management of kidney cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2012
|
Chiong, Edmund
|
|
2012
|
13 |
11 |
p. e482-e491
nvt p.
|
artikel
|
| 28 |
MDM2 inhibition in liposarcoma: a step in the right direction
|
Constantinidou, Anastasia
|
|
2012
|
13 |
11 |
p. 1070-1071
2 p.
|
artikel
|
| 29 |
Menarche, menopause, and breast cancer risk
|
Britt, Kara
|
|
2012
|
13 |
11 |
p. 1071-1072
2 p.
|
artikel
|
| 30 |
Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies
|
|
|
2012
|
13 |
11 |
p. 1141-1151
11 p.
|
artikel
|
| 31 |
Modern cancer management and research in the Middle East
|
El Saghir, Nagi S
|
|
2012
|
13 |
11 |
p. 1076-1078
3 p.
|
artikel
|
| 32 |
New vaccine for cervical cancer shows promise
|
Tanday, Sanjay
|
|
2012
|
13 |
11 |
p. e469-
1 p.
|
artikel
|
| 33 |
Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study
|
Kantarjian, Hagop
|
|
2012
|
13 |
11 |
p. 1096-1104
9 p.
|
artikel
|
| 34 |
Predicting the future of advanced prostate cancer
|
Sørensen, Karina Dalsgaard
|
|
2012
|
13 |
11 |
p. 1067-1068
2 p.
|
artikel
|
| 35 |
Preoperative chemotherapy for colon cancer is getting closer
|
Cervantes, Andrés
|
|
2012
|
13 |
11 |
p. 1073-1074
2 p.
|
artikel
|
| 36 |
Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study
|
Olmos, David
|
|
2012
|
13 |
11 |
p. 1114-1124
11 p.
|
artikel
|
| 37 |
Rad Art: A Journey Through Radiation Treatment
|
Mastrianni, David M
|
|
2012
|
13 |
11 |
p. 1085-
1 p.
|
artikel
|
| 38 |
S-1 in colorectal cancer: a new standard of care?
|
Grothey, Axel
|
|
2012
|
13 |
11 |
p. 1068-1070
3 p.
|
artikel
|
| 39 |
SIOP Annual Congress
|
Collingridge, David
|
|
2012
|
13 |
11 |
p. 1082-
1 p.
|
artikel
|
| 40 |
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial
|
Hong, Yong Sang
|
|
2012
|
13 |
11 |
p. 1125-1132
8 p.
|
artikel
|
| 41 |
Supportive, palliative, and end-of-life care for patients with cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2012
|
Payne, Sheila
|
|
2012
|
13 |
11 |
p. e492-e500
nvt p.
|
artikel
|
| 42 |
Swiss vote “no” to comprehensive smoking ban
|
Burki, Talha Khan
|
|
2012
|
13 |
11 |
p. e466-
1 p.
|
artikel
|
| 43 |
Tackling cancer burden in the Middle East: Qatar as an example
|
Brown, Robert
|
|
2012
|
13 |
11 |
p. e501-e508
nvt p.
|
artikel
|
| 44 |
The limitations of imaging response criteria
|
Mehta, Ankit I
|
|
2012
|
13 |
11 |
p. 1064-1065
2 p.
|
artikel
|
| 45 |
Tobacco control in the Middle East
|
Burki, Talha Khan
|
|
2012
|
13 |
11 |
p. 1079-
1 p.
|
artikel
|
| 46 |
Treatment of breast cancer during pregnancy
|
Gajjar, Ketan
|
|
2012
|
13 |
11 |
p. e460-
1 p.
|
artikel
|
| 47 |
Treatment options in elderly patients with glioblastoma
|
Sharma, Aman
|
|
2012
|
13 |
11 |
p. e460-e461
nvt p.
|
artikel
|
| 48 |
Treatment options in elderly patients with glioblastoma – Authors' reply
|
Malmström, Annika
|
|
2012
|
13 |
11 |
p. e461-e462
nvt p.
|
artikel
|
| 49 |
UK cancer death rates to decrease by 2030
|
Whinder, Frances
|
|
2012
|
13 |
11 |
p. e467-
1 p.
|
artikel
|
| 50 |
Voices from the front: November
|
Mastrianni, David M
|
|
2012
|
13 |
11 |
p. 1086-
1 p.
|
artikel
|
| 51 |
When David lost his voice
|
Smith, Lan-Lan
|
|
2012
|
13 |
11 |
p. 1086-
1 p.
|
artikel
|
| 52 |
Who should receive EGFR tyrosine-kinase inhibitors?
|
Yu, Helena A
|
|
2012
|
13 |
11 |
p. 1074-1076
3 p.
|
artikel
|
Tijdschrift beschrijving